Key Points
- Insider sale: Roy Hardiman sold 2,692 Alumis shares for approximately $70,988 at an average price of $26.37, reducing his ownership by 1.28% to 207,746 shares.
- Mixed financial performance: Alumis reported a quarterly loss of $0.74 per share, slightly worse than estimates, while revenue of $1.74 million also fell short of the $2.10 million consensus.
- Analyst outlook remains generally positive: The stock has a “Moderate Buy” consensus rating and a $40.30 average price target, although HC Wainwright maintained a “Neutral” view and several insiders recently sold shares.
Alumis Inc. (NASDAQ:ALMS - Get Free Report) insider Sanam Pangali sold 1,364 shares of the company's stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $35,968.68. Following the sale, the insider directly owned 9,747 shares of the company's stock, valued at approximately $257,028.39. This represents a 12.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Sanam Pangali also recently made the following trade(s):
- On Monday, July 6th, Sanam Pangali sold 5,000 shares of Alumis stock. The shares were sold at an average price of $28.00, for a total value of $140,000.00.
Alumis Stock Performance
NASDAQ:ALMS opened at $27.12 on Thursday. The firm has a market cap of $3.46 billion, a P/E ratio of -13.70 and a beta of -0.69. The stock's 50 day simple moving average is $25.37 and its 200-day simple moving average is $25.22. Alumis Inc. has a 12-month low of $3.76 and a 12-month high of $31.35.
Alumis (NASDAQ:ALMS - Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.01). Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%.The company had revenue of $1.74 million for the quarter, compared to analyst estimates of $2.10 million. Research analysts forecast that Alumis Inc. will post -2.87 EPS for the current fiscal year.
Key Alumis News
Here are the key news stories impacting Alumis this week:
- Neutral Sentiment: HC Wainwright reaffirmed its “Neutral” rating on Alumis, indicating the analyst does not currently see a strong enough catalyst to support a more bullish view. HC Wainwright Reaffirms Neutral Rating for Alumis
- Negative Sentiment: Six company insiders, including CFO John R. Schroer, sold a combined 14,953 shares of Alumis on August 3 at an average price of $26.37, generating approximately $394,311 in proceeds. The sales reduced individual holdings by roughly 1.28% to 12.28%; the CFO’s position declined 11.72%. While insider sales can reflect personal financial planning rather than a change in business outlook, the concentration of sales may weigh on investor sentiment. The transactions were reported in SEC filings for Read More., Read More., Read More., Read More., Read More., and Read More..
Analyst Ratings Changes
A number of equities analysts have recently weighed in on the company. Wall Street Zen cut Alumis from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. HC Wainwright reissued a "neutral" rating and issued a $25.00 target price on shares of Alumis in a research note on Monday. Wells Fargo & Company boosted their target price on shares of Alumis from $49.00 to $51.00 and gave the company an "overweight" rating in a research note on Friday, May 15th. Morgan Stanley restated an "overweight" rating and set a $39.00 target price on shares of Alumis in a research report on Friday, May 15th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Alumis in a research report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $40.30.
Check Out Our Latest Stock Analysis on Alumis
Institutional Trading of Alumis
Several institutional investors have recently added to or reduced their stakes in ALMS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Alumis by 64.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company's stock worth $77,000 after buying an additional 4,926 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Alumis by 24.0% in the first quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company's stock worth $378,000 after acquiring an additional 11,949 shares during the last quarter. Jane Street Group LLC acquired a new position in Alumis in the first quarter valued at approximately $111,000. Rhumbline Advisers boosted its stake in Alumis by 21.7% in the first quarter. Rhumbline Advisers now owns 16,543 shares of the company's stock valued at $102,000 after acquiring an additional 2,949 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Alumis by 163.2% during the second quarter. Geode Capital Management LLC now owns 1,167,832 shares of the company's stock valued at $3,504,000 after purchasing an additional 724,133 shares during the last quarter.
About Alumis
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
